Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 27.75 INR
Change Today +0.20 / 0.73%
Volume 2.4K
KILD On Other Exchanges
Symbol
Exchange
KILD is not on other exchanges.
As of 7:06 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

kilitch drugs (india) ltd (KILD) Snapshot

Open
28.75
Previous Close
27.55
Day High
28.75
Day Low
27.05
52 Week High
01/7/15 - 56.50
52 Week Low
08/4/14 - 20.55
Market Cap
367.2M
Average Volume 10 Days
12.7K
EPS TTM
-0.22
Shares Outstanding
13.2M
EX-Date
09/24/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KILITCH DRUGS (INDIA) LTD (KILD)

Related News

No related news articles were found.

kilitch drugs (india) ltd (KILD) Related Businessweek News

No Related Businessweek News Found

kilitch drugs (india) ltd (KILD) Details

Kilitch Drugs (India) Limited, a pharmaceutical company, manufactures and markets various formulations in solid, liquid, and parenteral dosage forms primarily in India. It manufactures antibacterial parenteral formulations and produces sterile liquid formulations. The company offers gastroenterology, anti-anginal, anti-convulsant, anti–inflammatory, anti-malarial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anaesthetic, neurotonic, epileptic, external preparation, veterinary, and contrast media products. Its products also include non steroidal anti inflammatory drugs; aminoglycosides; antibacterials; iron supplements for the treatment of anemia; uterine stimulants; local anesthetic products; and other products. In addition, the company provides contract manufacturing services to pharmaceutical companies. Kilitch Drugs (India) Limited also exports its products primarily to Benin, Togo, Burkina Faso, Mali, Niger, Ivory Coast, Tchad, Cameroon, Senegal, Rwanda, Gabon, Congo, Sudan, South Sudan, Namibia, South Africa, Zambia, Guinea Conakry, Nigeria, Mauritania, Papua New Guinea, Ethiopia, Sri Lanka, Cambodia, and Vietnam; and supplies products of various manufacturers. The company was incorporated in 1992 and is headquartered in Mumbai, India. Kilitch Drugs (India) Limited is a subsidiary of Kilitch Company Pharma Limited.

Founded in 1992

kilitch drugs (india) ltd (KILD) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kilitch drugs (india) ltd (KILD) Key Developments

Kilitch Drugs (India) Limited Announces Audited Standalone Earnings Results for the Fourth Quarter and Consolidated and Standalone Earnings Results for the Full Year Ended March 31, 2015

Kilitch Drugs (India) Limited announced audited standalone earnings results for the fourth quarter and consolidated and standalone earnings results for the full year ended March 31, 2015. For the quarter, on standalone basis, the company reported loss from operations before other income, interest & exceptional items of INR 18.928 million against INR 42.874 million for the same period of last year. Loss from ordinary activities before tax was INR 11.803 million against INR 25.388 million for the same period of last year. Net loss for the period was INR 12.673 million or INR 0.96 per basic and diluted share against INR 18.454 million or INR 1.39 per basic and diluted share for the same period of last year. Net sales/income from operations was INR 32.240 million against INR 63.357 million for the same period of last year. For the year, on standalone basis, the company reported loss from operations before other income, interest & exceptional items of INR 35.347 million against INR 52.282 million for the same period of last year. Loss from ordinary activities before tax was INR 8.444 million against profit from ordinary activities before tax of INR 10.629 million for the same period of last year. Net loss for the period was INR 1.855 million or INR 0.14 per basic and diluted share against net profit of INR 11.765 million or INR 0.89 per basic and diluted share for the same period of last year. Net sales/income from operations was INR 184.373 million against INR 142.149 million for the same period of last year. For the year, on consolidated basis, the company reported loss from operations before other income, interest & exceptional items of INR 36.692 million, loss from ordinary activities before tax of INR 9.484 million, and net loss for the period of INR 2.894 million or INR 0.02 per basic and diluted share.

Kilitch Drugs India Approves Delisting Of The Company From National Stock Exchange of India

Kilitch Drugs India Ltd announced that at Board of Directors of the company at its meeting held on April 14, 2015, has approved the delisting of the company's securities from National Stock Exchange of India Limited, but will continue to be listed on Bombay Stock Exchange Limited, being the Regional Stock Exchange of the company.

Kilitch Drugs (India) Limited to Report Q4, 2015 Results on May 28, 2015

Kilitch Drugs (India) Limited announced that they will report Q4, 2015 results on May 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KILD:IN 27.75 INR +0.20

KILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KILD.
View Industry Companies
 

Industry Analysis

KILD

Industry Average

Valuation KILD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.8x
Price/Book 12.3x
Price/Cash Flow 23.1x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KILITCH DRUGS (INDIA) LTD, please visit www.kilitch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.